Listen
AVASTIN (bevacizumab), monoclonal antibody
TRANSPARENCY COMMITTEE OPINION
Opinions on drugs -
Posted on
Oct 13 2016
Reason for request
Re-assessment of the actual benefit and the improvement in actual benefit
No clinical benefit demonstrated in first-line of non-squamous locally advanced or metastatic non-small cell lung cancer.
- AVASTIN has Marketing Authorisation in combination with platinum-based chemotherapy, in first-line treatment of adult patients with advanced and inoperable, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.
- It is part of the first-line options in treatment of NSCLC.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
